Adam Grossman

Dr. Adam Grossman is Praedicat's Vice President of Modeling, Senior Scientist and one of Praedicat's co-founders. Adam works on the modeling team to create and implement Praedicat's risk models. Previously, Adam was an Analyst in the Emerging Risk Solutions group at RMS where he was a core member of the liability catastrophe research and development team that formed the foundation for Praedicat. Adam received his B.A.Sc. in Engineering Science from the University of Toronto, after developing flight training simulators at Defense R&D Canada. He then went on to earn his M.S. and Ph.D. in Bioengineering from Stanford University.

Perfluorinated chemicals linked to weight gain

Perfluorinated chemicals linked to weight gain 150 150 Adam Grossman

Praedicat has been tracking perfluorinated chemicals (PFCs) since our inception. They are used in a wide range of applications, including fire retardant foams, food-contact materials, water repellents like Scotchgard, and…

read more

Evidence for a cell phone-cancer link is more tenuous than ever

Evidence for a cell phone-cancer link is more tenuous than ever 150 150 Adam Grossman

In May 2016, the U.S. National Toxicology Program (NTP) released partial and preliminary findings from a series of 2-year studies designed to test whether cell phones can cause cancer. As we…

read more

Personal exposure monitoring could be the next driver of litigation

Personal exposure monitoring could be the next driver of litigation 150 150 Adam Grossman

One of the main impediments to understanding environmental drivers of disease is having an accurate assessment of exposure.  This article shows why this barrier is beginning to vanish by detailing…

read more

Praedicat and AIG publish white paper on additive manufacturing

Praedicat and AIG publish white paper on additive manufacturing 150 150 Adam Grossman

Additive manufacturing, also known as 3D printing, has the potential to revolutionize many industries.  But like any new innovation, it creates new risks. The Praedicat approach to risk identification is…

read more

NTP prepares to classify antimony trioxide as a carcinogen

NTP prepares to classify antimony trioxide as a carcinogen 150 150 Adam Grossman

The U.S. National Toxicology Program (NTP) recently completed its draft evaluation of antimony trioxide as a human carcinogen. While the draft is still open for peer review and comment, the…

read more

Generic Drugs, Federal Preemption, and FDA Rulemaking

Generic Drugs, Federal Preemption, and FDA Rulemaking 150 150 Adam Grossman

Praedicat’s new modeling capabilities in the pharmaceutical space present both opportunities for modeling and challenges arising in the ever-changing landscape of federal pharmaceutical law and regulation.  To illustrate how we…

read more